Orgenesis, a pioneering, global biotech company committed to lowering costs, accelerating commercialization, and transforming the delivery of cell and gene therapies (CGTs), announced it has entered into an agreement to acquire the assets of Tamir Biotechnology, Inc. (“TamirBio”), including ranpirnase, TamirBio’s broad spectrum anti-viral platform.
Mark Cohen, Senior Partner and the Chair of the Life Science Practice Group, represents Orgenesis in its commercial, corporate and intellectual property matters.
To read the full article, click here.
